Status:

UNKNOWN

Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer

Lead Sponsor:

Shenzhen People's Hospital

Conditions:

Carcinoma, Non-Small Cell Lung

Carcinoma, Small Cell Lung

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

Brief Summary

Various of immunotherapies are now widely applied in the treatment of lung cancer. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal...

Detailed Description

Cancer genome research has exploded benefits from the application of modern high-throughput genome sequencing in the past few years. Since usually there are no common antigens expressed on the surface...

Eligibility Criteria

Inclusion

  • Age ≥18 years ≤ 70 years at the time of informed consent
  • Signed informed consent to be provided
  • pathologically confirmed lung cancer
  • failed in previous standard chemotherapy and targeted therapy
  • Life expectancy not less than 90 days
  • Karnofsky performance status 0-1
  • adequate organ functions

Exclusion

  • Actively infectious condition including hepatitis
  • Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.
  • Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).
  • Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).
  • Active systemic infections, coagulation disorders or any other active major medical illnesses.
  • Patients who are receiving any other investigational agents.

Key Trial Info

Start Date :

April 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2020

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03871205

Start Date

April 1 2019

End Date

December 30 2020

Last Update

March 12 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shenzhen People's Hospital

Shenzhen, Guangdong, China, 518020